美多巴联合普拉克索治疗帕金森病的效果(1)
[摘要]目的 探討美多巴联合普拉克索对帕金森病(PD)患者认知功能及生活质量的影响。方法 选取2016年1月～2018年1月我院收治的126例PD患者作为研究对象，将其随机分为美多巴组(n=63)和普拉克索组(n=63)。美多巴组患者给予美多巴治疗，普拉克索组患者在以上治疗基础上给予普拉克索治疗。比较两组患者的治疗效果。结果 治疗后，两组患者的帕金森评分量表Ⅲ(UPDRSⅢ)评分低于治疗前，而蒙特利尔认知量表(MoCA)及简易精神状态评价量表(MMSE)评分高于治疗前，且普拉克索组患者的UPDRSⅢ评分低于美多巴组，MoCA及MMSE评分高于美多巴组，差异有统计学意义(P<0.05)。治疗后，两组患者的血清谷胱甘肽(GSH)、谷胱甘肽过氧化物酶(GSH-Px)水平明显高于治疗前，活性氧(ROS)水平明显低于治疗前，且普拉克索组患者的血清GSH、GSH-Px水平明显高于美多巴组，ROS水平明显低于美多巴组，差异有统计学意义(P<0.05)。普拉克索组患者的生理、心理、独立性、社会关系及环境5个维度评分均高于美多巴组，差异有统计学意义(P<0.05)。普拉克索组和美多巴组不良反应总发生率分别为6.35%和12.70%，两组比较，差异无统计学意义(P>0.05)。结论 美多巴联合普拉克索治疗PD患者，可有效缓解患者的相关临床症状，提高其认知功能及生活质量，临床应用安全、有效。
[关键词]美多巴；普拉克索；帕金森病；认知功能；生活质量
[中图分类号] R742.5 [文献标识码] A [文章编号] 1674-4721(2018)3(c)-0093-04
[Abstract]Objective To investigate the effect of Medopa combined with Pramipexole on cognitive function and quality of life (QOL) in patients with Parkinson′s disease (PD).Methods From January 2016 to January 2018，126 patients with PD admitted in our hospital were selected as subjects.They were randomly divided into Medodopa group (n=63) and Pramipexole group (n=63).Medopa group was treated with Medopa，while the Pramipexole group was treated with Pramipexole on the basis of above treatment.The therapeutic effect were compared between the two groups.Results After treatment，the score of Parkinson′s scale Ⅲ (UPDRSⅢ) was significantly lower than that before treatment，the Montreal cognitive scale (MoCA) and simple mental state evaluation scale (MMSE) were significantly lower than those before treatment，whlie the score of UPDRSⅢ in Pramipexole group was significantly lower than that in Medopa group，the scores of MoCA and MMSE were significantly higher than those in Pramipexole group，the differences were statistically significant (P<0.05).After treatment，two groups of patients with levels of serum glutathione (GSH) and glutathione peroxidase (GSH-Px) were significantly higher than those before treatment，the level of reactive oxygen species (ROS) was lower than that before treatment，and the levels of GSH and GSH-Px in the Pramipexole group were significantly higher than those in Medopa group，the ROS level was significantly lower than that in Medopa group，the differences were statistically significant (P<0.05).The physical，psychological，independence，social relationship and environment of the Pramipexole group were all higher than those of the Medopa group，the differences were statistically significant (P<0.05).The total incidence of adverse reactions in Pramipexole group was 6.35%，and it was 12.70% in the Medopa grou，and the difference was not statistically significant (P>0.05).Conclusion The clinical symptoms of PD patients can be effectively alleviated by the combination of Medopa and Pramipexole.It can improve its cognitive function and quality of life，clinical application is safe and effective., http://www.100md.com(王雷)
[关键词]美多巴；普拉克索；帕金森病；认知功能；生活质量
[中图分类号] R742.5 [文献标识码] A [文章编号] 1674-4721(2018)3(c)-0093-04
[Abstract]Objective To investigate the effect of Medopa combined with Pramipexole on cognitive function and quality of life (QOL) in patients with Parkinson′s disease (PD).Methods From January 2016 to January 2018，126 patients with PD admitted in our hospital were selected as subjects.They were randomly divided into Medodopa group (n=63) and Pramipexole group (n=63).Medopa group was treated with Medopa，while the Pramipexole group was treated with Pramipexole on the basis of above treatment.The therapeutic effect were compared between the two groups.Results After treatment，the score of Parkinson′s scale Ⅲ (UPDRSⅢ) was significantly lower than that before treatment，the Montreal cognitive scale (MoCA) and simple mental state evaluation scale (MMSE) were significantly lower than those before treatment，whlie the score of UPDRSⅢ in Pramipexole group was significantly lower than that in Medopa group，the scores of MoCA and MMSE were significantly higher than those in Pramipexole group，the differences were statistically significant (P<0.05).After treatment，two groups of patients with levels of serum glutathione (GSH) and glutathione peroxidase (GSH-Px) were significantly higher than those before treatment，the level of reactive oxygen species (ROS) was lower than that before treatment，and the levels of GSH and GSH-Px in the Pramipexole group were significantly higher than those in Medopa group，the ROS level was significantly lower than that in Medopa group，the differences were statistically significant (P<0.05).The physical，psychological，independence，social relationship and environment of the Pramipexole group were all higher than those of the Medopa group，the differences were statistically significant (P<0.05).The total incidence of adverse reactions in Pramipexole group was 6.35%，and it was 12.70% in the Medopa grou，and the difference was not statistically significant (P>0.05).Conclusion The clinical symptoms of PD patients can be effectively alleviated by the combination of Medopa and Pramipexole.It can improve its cognitive function and quality of life，clinical application is safe and effective., http://www.100md.com(王雷)